GlassScriptPhysician profile
David R Neiger
NPI 1457335358
$1,879.36
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $791 · 2021: $32.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $494.00 | 2020 | |
| Novo Nordisk INC | $373.53 | 2019-2020 | |
| Amgen INC. | $175.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $153.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.70 | 2019-2020 | |
| Lilly USA, LLC | $126.67 | 2019-2020 | |
| Amarin Pharma, INC. | $80.33 | 2019-2020 | |
| Gilead Sciences, INC. | $67.20 | 2019-2020 | |
| Pfizer INC. | $47.84 | 2019-2021 | |
| Allergan, INC. | $46.76 | 2020 | |
| Merck Sharp & Dohme LLC | $36.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.88 | 2019 | |
| Abbott Laboratories | $19.00 | 2019 | |
| Glaxosmithkline, LLC. | $17.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.26 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.87 | 2019 | |
| Daiichi Sankyo INC. | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Neiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.